Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo
Open Access
- 2 March 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 59 (4), 658-665
- https://doi.org/10.1093/jac/dkl563
Abstract
The in vitro and in vivo efficacy and drug–drug interactions of the novel semi-synthetic endoperoxide artemisone with standard antimalarials were investigated in order to provide the basis for the selection of the best partner drug. Antimalarial activity and drug interactions were evaluated in vitro against Plasmodium falciparum by the incorporation of [3H]hypoxanthine. In vivo efficacy and drug interactions were assessed using the standard 4-day Peters' test. Artemisone was 10 times more potent than artesunate in vitro against a panel of 12 P. falciparum strains, independent of their susceptibility profile to antimalarial drugs, and consistently 4 to 10 times more potent than artesunate in rodent models against drug-susceptible and primaquine- or sulfadoxine/pyrimethamine-resistant Plasmodium berghei lines and chloroquine- or artemisinin-resistant lines of Plasmodium yoelii. Slight antagonistic trends were found between artemisone and chloroquine, amodiaquine, tafenoquine, atovaquone or pyrimethamine and additive to slight synergistic trends with artemisone and mefloquine, lumefantrine or quinine. Various degrees of synergy were observed in vivo between artemisone and mefloquine, chloroquine or clindamycin. These results confirm the increased efficacy of artemisone over artesunate against multidrug-resistant P. falciparum and provide the basis for the selection of potential partner drugs for future deployment in areas of multidrug-resistant malaria. Artemisone represents an important addition to the repertoire of artemisinin combination therapies currently in use, as it has enhanced antimalarial activity, improved bioavailability and stability over current endoperoxides.Keywords
This publication has 31 references indexed in Scilit:
- Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistanceTrends in Molecular Medicine, 2006
- Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6The Lancet, 2005
- ASSOCIATION OF FAILURES OF SEVEN-DAY COURSES OF ARTESUNATE IN A NON-IMMUNE POPULATION IN BANGUI, CENTRAL AFRICAN REPUBLIC WITH DECREASED SENSITIVITY OF PLASMODIUM FALCIPARUMThe American Journal of Tropical Medicine and Hygiene, 2005
- Artemisinin-based combination therapies (ACTs): Best hope for malaria treatment but inaccessible to the needy!Acta Tropica, 2005
- Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trialThe Lancet, 2005
- Combination Therapy Counteracts the Enhanced Transmission of Drug-Resistant Malaria Parasites to MosquitoesAntimicrobial Agents and Chemotherapy, 2004
- Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trialThe Lancet, 2002
- Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective studyThe Lancet, 2000
- The chemotherapy of rodent malaria. LVIII. Drug combinations to impede the selection of drug resistance, Part. 2: The new generation--artemisinin or artesunate with long-acting blood schizontocides.Pathogens and Global Health, 2000
- Assessment of the pharmacodynamic properties of antimalarial drugs in vivoAntimicrobial Agents and Chemotherapy, 1997